A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (NEST)

NCT01622361 Phase 3 UNKNOWN

The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast cancer in premenopausal women.

Details

Lead sponsor	Asan Medical Center
Phase	Phase 3
Status	UNKNOWN
Enrolment	290
Start date	2012-06
Completion	2016-02

Conditions

• Breast Cancer

Interventions

• Adriamycin+Cyclophosphamide>Docetaxel
• GnRHa with Tamoxifen

Primary outcomes

• Response Rate — 6 months

Countries

South Korea